How can we find novel natural products from Actinomycetes that act as growth modulators on mammalian cells? Can we harvest and develop the potential of these novel compounds for industrial and medical biotechnology?

Can light-activatable ruthenium compounds be used as a more selective anticancer treatment?

Promotores: J. Jonkers, K.E. de Visser

Cancer is the leading cause of death in the Netherlands, and, with over 100 different types of cancer, it’s not a simple disease. Today, skin, breast, lung, prostate and colon cancer are the most diagnosed forms. Therefore, the discovery and development of new drugs has the ability to significantly…

In this thesis, we will utilize embryonic zebrafish tumour models to understand the interaction between engrafted human cancer cells and macrophages from the host, test drug administration modalities and anti-cancer efficacies of newly-developed PDT and PACT compounds, and test a light-triggered liposomal…

Promotor: E. Bouwman, Co-promotor: S. Bonnet

Researchers of the Leiden University Medical Centre (LUMC) and the Leiden Institute of Chemistry have made an important discovery about the commonly used anti-cancer drug doxorubicin. They have found a way to reduce its side effects without sacrificing the effectiveness of the medication. This is encouraging…

Metal-containing molecules combine geometrical features and a reactivity that are inherently different from that of organic molecules. My research focuses on light-activatable metal-based anticancer drugs and metal-functionalized liposomes. Light is a very selective way to activate photosensitive drugs…

How can zebrafish research help to understand and fight human cancer?

Promotor: Prof.dr. R. Verpoorte, , Co-Promotor: Young Hae Choi

In photoactivated chemotherapy (PACT), a biologically active compound is caged by a light-cleavable protecting group.

A full overview of MCBIM PhD theses.

As leading cause of death worldwide, cancer is responsible for nearly 10 million deaths in 2020 according to World Health Organization (WHO). Cisplatin and its derivatives are commonly used chemotherapy agents for current cancer treatment in the clinics.

One of the main challenges in the development of an effective anti-cancer vaccine is the generation of an adequate and directed cellular immune response.

How can new compounds relieve cancer patients of severe side effects?

Former masterstudent Bio-Pharmaceutical Sciences Maddalena Centanni will be awarded the 2020 Arenberg Coimbra Prize for Erasmus Students. Centanni spent her six month Erasmus exchange at Uppsala Universiy in Sweden where she looked for ways to improve anti-cancer drug dosing.

PhD defence

Promotores: Prof.dr. P.C.W. Hogendoorn & Prof.dr. H.P. Spaink, Co-promotor: Dr. B.E. Snaar-Jagalska

Last year, chemists Dennis Wander and Hermen Overkleeft contributed to an important discovery about a widely used cancer drug. Their research has now been recognised as Finalist for the PNAS Cozzarelli Prize in the Biomedical Sciences class.

Monoacylglycerol lipase (MAGL) is the principal enzyme responsible for hydrolysis of the endocannabinoid 2-arachidonoylglycerol (2-AG). MAGL inhibition provides several potential therapeutic opportunities, including anti-nociceptive, anti-inflammatory and anti-cancer activity.

Researchers from Leiden University Medical Center (LUMC) and Netherlands Cancer Institute (NKI) have discovered how specialised immune cells can detect and remove cancers that are ‘invisible’ to the conventional defence mechanisms of the immune system. Their work has been published in Nature. The findings…

Cytotoxic T-cells (CTLs) are involved in the clearance of viruses and killing of tumor cells.

PhD defence

Lecture

How do macrophages and neutrophils contribute to metastatic onset?

PhD defence

Streptomyces bacteria are a valuable source of natural products, many of which are used in the clinic or in biotechnology.

Metal complexes and 2D materials like graphene were combined to produce structures that can function as sensors.

Filamentous Actinobacteria, such as Streptomyces, produce a plethora of chemically diverse bioactive metabolites that have found applications across medicine, agriculture and biotechnology.

Promotor: G.P. van Wezel, Co-promotor: D. Claessen

Promotor: G.P. van Wezel

Animal Sciences’ contribution to the Bioactive Molecules research theme includes research on molecules from natural sources, such as plants, insects, and snake venom, with the aim to identify novel anti-cancer, anti-inflammatory, anti-microbial, and anti-diabetic agents.

In order to be able to develop effective medicine and treatments to prevent or cure autoimmune diseases or cancer we need to understand the mechanisms how they arise and what drives their course.Unravelling the fundamental molecular mechanisms influencing the onset and course of diseases such as allergies,…

Leiden PhD student Xuequan Zhou has designed a new promising molecule that efficiently kills cancer cells, but does not harm healthy tissue. The trick: the drug is only active when irradiated with light. Zhou’s new compound does this extra efficiently by cleverly self-organising into nanoparticles.…

Chemotherapy that does not harm the body, but effectively fights cancer cells: that is the goal of chemist Sylvestre Bonnet and his team. During his PhD research, chemist Xuequan Zhou brought that goal a little closer. He developed molecules that, upon injection in the bloodstream, self-assemble into…

Lecture

Research at the MCBIM group is comprised of the following research themes:

Plant Sciences' contribution to the Bioactive Molecules research theme is to identify new plant bioactive molecules, and unravel their mechanisms of action in plant development or health, and the regulatory networks and (bio)synthetic pathways required for their production.

In the research programme Microbial Sciences we perform state-of-the-art research in the field of biotechnology and microbial sciences.

Supervisor: Anna Vlachodimou

How does the extracellular matrix coordinate endothelial cell behavior during angiogenesis, and how do metabolic waste-products and matrix-degrading enzymes produced by the tumour modify the extracellular matrix so as the change the cellular coordination?

Biological chemist Nathaniel Martin and his team received an NWO grant to examine how blocking a specific enzyme in our body, NNMT, could be helpful in the treatment of some cancers. Trials with mice have been promising, and together with the Netherlands Cancer Institute, Martin wants to take the next…

Aukje Beers combined theory and practice, as well as chemistry, biology, and computer models. In this way, she discovered two protein inhibitors during her master’s project that could contribute to the development of a new cancer drug. For her research, Beers received the Unilever Research Prize on…

An international group of scientists has discovered that certain cells of our immune system – the so-called T cells – communicate with each other and work together as a team. To fight an infection they stimulate each other’s growth, but at the same time, they inhibit each other when there is a surplus…

Providing each cancer patient with the right treatment remains a challenge. Oncode Accelerator aims to change this by innovating the way we develop cancer treatments, thus ensuring the patient is at the heart of the process. Leiden University, the LUMC and other partners will implement this new way…

Can we bring novel treatment options to the clinic for UM patients with liver metastases?

How can cell wall engineering approaches be used to improve streptomycetes for industry to make new antibiotics?

Nature is a never-ending source of inspiration for the researchers at the Institute of Biology Leiden (IBL). Based on a better fundamental understanding of nature, they are able to seek solutions in the area of health and biodiversity. The theme of IBL is ‘Harnessing biodiversity for health.’

Ewa Snaar-Jagalska, Shuning He and colleagues from IBL, LION and LACDR reported on a new zebrafish study to understand micrometastasis of human cancer cells. They discovered a novel role for neutrophils in assisting metastasis formation, which provides critical insights for anti-cancer therapies.

PhD research recently completed by pharmacologist Margreke Brill shows that morbidly obese patients should be given a different dosage of the drugs Cefazolin and Midazolam. This could also apply to other drugs such as anti-cancer drugs as well as antibiotics and Margreke Brill is advocating a change…